Clinical Trial Update: Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma [Phase 2]

View source ↗

Summary

This clinical trial update reports that the Phase 2 study of binimetinib plus nivolumab in BRAF V600 wildtype cutaneous melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma

Drugs mentioned

• Binimetinib (binimetinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Status: TERMINATED